Phenotypic In Vivo Screening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates

[1]  J. Vane,et al.  Anti-inflammatory drugs and their mechanism of action , 1998, Inflammation Research.

[2]  N. Inagaki,et al.  Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone. , 2006, European journal of pharmacology.

[3]  R. DuBois,et al.  COX-2 inhibition and colorectal cancer. , 2004, Seminars in oncology.

[4]  C. Teter,et al.  Treatment of Affective Disorder and Obesity with Topiramate , 2000, The Annals of pharmacotherapy.

[5]  J. Buccafusco,et al.  The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist. , 2000, The Journal of pharmacology and experimental therapeutics.

[6]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[7]  K. Gadde,et al.  Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. , 2002, Obesity research.

[8]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[9]  Sean Ekins,et al.  In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.

[10]  J. Cryan,et al.  The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice , 2005, Neuroscience & Biobehavioral Reviews.

[11]  F. Sinicrope.  Targeting cyclooxygenase‐2 for prevention and therapy of colorectal cancer , 2006, Molecular carcinogenesis.

[12]  J. Buccafusco,et al.  The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates , 2008, Psychopharmacology.

[13]  S. Zamvil,et al.  Statins and demyelination. , 2008, Current topics in microbiology and immunology.

[14]  J. Bryans,et al.  3‐Substituted GABA analogs with central nervous system activity: A review , 1999, Medicinal research reviews.

[15]  Louis A Tartaglia.  Complementary new approaches enable repositioning of failed drug candidates , 2006, Expert opinion on investigational drugs.

[16]  P. E. Gold,et al.  Attenuation of scopolamine-induced amnesia in mice , 1988, Psychopharmacology.

[17]  G. Keating,et al.  Raloxifene , 2012, Drugs.

[18]  R. Peterson,et al.  Systematizing Serendipity for Cardiovascular Drug Discovery , 2009, Circulation.

[19]  Jennie Z Ma,et al.  Oral topiramate for treatment of alcohol dependence: a randomised controlled trial , 2003, The Lancet.

[20]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[21]  D. Baker,et al.  Inflammation in neurodegenerative diseases , 2010, Immunology.

[22]  G. Woodruff,et al.  The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed byd-serine , 1996, Psychopharmacology.

[23]  L. Vallée,et al.  Topiramate: efficacy and tolerability in children according to epilepsy syndromes , 2003, Epilepsy Research.

[24]  J. Corbin,et al.  PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS , 2002, International journal of clinical practice.

[25]  B. Druker,et al.  Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib , 2003, Pharmacological Reviews.

[26]  M A Geyer,et al.  Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. , 1998, Schizophrenia bulletin.

[27]  J. Simard,et al.  Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity. , 1995, The Journal of investigative dermatology.

[28]  T. Jay,et al.  A pathophysiological paradigm for the therapy of psychiatric disease , 2005, Nature Reviews Drug Discovery.

[29]  R. Beltran,et al.  Pitfalls in health communication: healthcare policy, institution, structure, and process. , 2004, MedGenMed : Medscape general medicine.

[30]  T. Sanke,et al.  The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. , 2008, Diabetes research and clinical practice.

[31]  D. Drucker.  Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes , 2007, Diabetes Care.

[32]  M. Williams,et al.  Challenges in the Search for Drugs to Treat Central Nervous System Disorders , 2009, Journal of Pharmacology and Experimental Therapeutics.

[33]  J. Bovill.  Pharmacology and clinical action of COX-2 selective NSAIDs. , 2003, Advances in experimental medicine and biology.

[34]  G. Koch,et al.  Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease? , 2010, CNS neuroscience & therapeutics.

[35]  D. Flood,et al.  Characterization of Pharmacological and Wake-Promoting Properties of the Dopaminergic Stimulant Sydnocarb in Rats , 2011, Journal of Pharmacology and Experimental Therapeutics.

[36]  Magda Melchert,et al.  The thalidomide saga. , 2007, The international journal of biochemistry & cell biology.

[37]  U. Landmesser,et al.  Nonlipid-lowering effects of statins , 2005, Current treatment options in cardiovascular medicine.

[38]  S. Tonstad,et al.  A multicentre, randomized, double‐blind, placebo‐controlled, 1‐year study of bupropion SR for smoking cessation , 2003, Journal of internal medicine.

[39]  Marc K Hellerstein,et al.  Exploiting Complexity and the Robustness of Network Architecture for Drug Discovery , 2008, Journal of Pharmacology and Experimental Therapeutics.

[40]  Y. Chagnon,et al.  Genetics of obesity: advances from rodent studies. , 1996, Trends in genetics : TIG.

[41]  B. Munos.  Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[42]  K. Offord,et al.  Treatment of asthma with nebulized lidocaine: a randomized, placebo-controlled study. , 2004, The Journal of allergy and clinical immunology.

[43]  E. Fauman,et al.  Pharmacology and mechanism of action of pregabalin: The calcium channel α2–δ (alpha2–delta) subunit as a target for antiepileptic drug discovery , 2007, Epilepsy Research.

[44]  J. Corbin,et al.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.

[45]  B. Patterson,et al.  Topiramate augmentation in treatment‐resistant obsessive–compulsive disorder: a retrospective, open‐label case series , 2006, Depression and anxiety.

[46]  F. Rambert,et al.  Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. , 1990, European journal of pharmacology.

[47]  T. Brue,et al.  Medical Treatment of Cushing’s Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone , 2010, Neuroendocrinology.

[48]  M. Birnbaum,et al.  An energetic tale of AMPK-independent effects of metformin. , 2010, The Journal of clinical investigation.

[49]  J C Gingell,et al.  Sildenafil, a novel effective oral therapy for male erectile dysfunction. , 1996, British journal of urology.

[50]  E. Tobinick.  The value of drug repositioning in the current pharmaceutical market. , 2009, Drug news & perspectives.

[51]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[52]  R. Nagai,et al.  Adipose tissue inflammation in obesity and metabolic syndrome. , 2009, Discovery medicine.

[53]  Michel Bourin,et al.  Forced swimming test in mice: a review of antidepressant activity , 2004, Psychopharmacology.

[54]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[55]  S. Bryan,et al.  Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. , 2008, Health technology assessment.

[56]  Sanjay Joshua Swamidass,et al.  Mining small-molecule screens to repurpose drugs , 2011, Briefings Bioinform..

[57]  J. Clader.  The discovery of ezetimibe: a view from outside the receptor. , 2004, Journal of medicinal chemistry.

[58]  M. Karagianni,et al.  Favorable response to subcutaneous administration of infliximab in rats with experimental colitis. , 2005, World journal of gastroenterology.

[59]  Paul Gerrard,et al.  Mechanisms of modafinil: A review of current research , 2007, Neuropsychiatric disease and treatment.

[60]  K. Yonkers,et al.  Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder , 2002, Expert opinion on pharmacotherapy.

[61]  B. Spiegelman,et al.  PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth* , 2001, The Journal of Biological Chemistry.

[62]  L. Arnold.  Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. , 2007, Pain medicine.

[63]  P. Vaitkus,et al.  Drug-Eluting Stents To Prevent Reblockage of Coronary Arteries , 2003, The Journal of cardiovascular nursing.

[64]  R. DuBois,et al.  Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. , 2010, Gastroenterology clinics of North America.

[65]  S. Youssef,et al.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease , 2002, Nature.

[66]  S. Connor,et al.  Antidiabetic Efficacy of BRL 49653, a Potent Orally Active Insulin Sensitizing Agent, Assessed in the C57BL/KsJ db/db Diabetic Mouse by Non‐invasive 1H NMR Studies of Urine , 1997, The Journal of pharmacy and pharmacology.

[67]  C. Lipinski,et al.  The Lyn Kinase Activator MLR-1023 Is a Novel Insulin Receptor Potentiator that Elicits a Rapid-Onset and Durable Improvement in Glucose Homeostasis in Animal Models of Type 2 Diabetes , 2012, Journal of Pharmacology and Experimental Therapeutics.

[68]  J. Oakman,et al.  An open trial of topiramate in the treatment of generalized social phobia. , 2004, The Journal of clinical psychiatry.

[69]  M. Wadenberg.  Conditioned avoidance response in the development of new antipsychotics. , 2010, Current pharmaceutical design.

[70]  David Brown,et al.  Unfinished business: target-based drug discovery. , 2007, Drug discovery today.

[71]  T. Rozen.  Antiepileptic Drugs in the Management of Cluster Headache and Trigeminal Neuralgia , 2001, Headache.

[72]  E. Elinav,et al.  CCL2 (pM levels) as a therapeutic agent in inflammatory bowel disease models in mice , 2010, Inflammatory bowel diseases.

[73]  N. Thornberry,et al.  Discovery of JANUVIA TM (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes. , 2007 .

[74]  Sean Ekins,et al.  Finding Promiscuous Old Drugs for New Uses , 2011, Pharmaceutical Research.

[75]  S. Lukas,et al.  Buprenorphine treatment of refractory depression. , 1995, Journal of clinical psychopharmacology.

[76]  Jun O. Liu,et al.  A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.

[77]  Marc K Hellerstein,et al.  A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery. , 2008, Metabolic engineering.

[78]  A. Markham,et al.  Sildenafil: a review of its use in erectile dysfunction. , 1999, Drugs.

[79]  I. Bruce,et al.  Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. , 2006, Clinical and experimental rheumatology.

[80]  Sidney H Kennedy,et al.  Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. , 2002, Bipolar disorders.

[81]  K. Petersen,et al.  Mechanism by which metformin reduces glucose production in type 2 diabetes. , 2000, Diabetes.

[82]  B. Hawes,et al.  The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[83]  P. Ward,et al.  Molecular and Cellular Basis of Inflammation , 1999, Current Inflammation Research.

[84]  M. Siddiqui,et al.  Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. , 2005, Drugs.

[85]  H. Meltzer,et al.  In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. , 2008, Progress in brain research.

[86]  S. Irwin,et al.  Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse , 1968, Psychopharmacologia.

[87]  Mitchell A. Avery,et al.  Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity , 2004, Hypertension.

[88]  N. Chabbert-Buffet,et al.  Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. , 2005, Human reproduction update.

[89]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[90]  C. Serhan.  Systems approach to inflammation resolution: identification of novel anti‐inflammatory and pro‐resolving mediators , 2009, Journal of thrombosis and haemostasis : JTH.

[91]  K. Fouad,et al.  The unilateral 6‐OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis , 2005, The European journal of neuroscience.

[92]  G. Elmer,et al.  Drug discovery in psychiatric illness: mining for gold. , 2009, Schizophrenia bulletin.

[93]  A. Young,et al.  Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). , 1999, Diabetes.

[94]  N. Richard,et al.  Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study , 2005, Biological Psychiatry.

[95]  M. E. Kosman.  Evaluation of a new antihypertensive agent. Minoxidil. , 1980, JAMA.

[96]  Michael E. Furrow.  Pharmaceutical patent life-cycle management after KSR v. Teleflex. , 2008, Food and drug law journal.

[97]  J. Rundegren,et al.  Minoxidil: mechanisms of action on hair growth , 2004, The British journal of dermatology.

[98]  R. Stafford,et al.  Off-label prescribing among office-based physicians. , 2006, Archives of internal medicine.

[99]  M. Kakei,et al.  Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. , 2005, Endocrine journal.

[100]  D. Wong,et al.  Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors , 2001, Neuropsychopharmacology.

[101]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[102]  T. Heffner,et al.  Structure−Activity Relationships of Pregabalin and Analogues That Target the α2-δ Protein , 2005 .

[103]  N R Ackerman,et al.  Bronchodilator and antiulcer phenoxypyrimidinones. , 1980, Journal of medicinal chemistry.

[104]  H. Bischoff.  The mechanism of alpha-glucosidase inhibition in the management of diabetes. , 1995, Clinical and investigative medicine. Medecine clinique et experimentale.

[105]  The concept of depression as a dysfunction of the immune system. , 2010, Current immunology reviews.

[106]  David Jou,et al.  Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). , 2011, Journal of medicinal chemistry.